MDACC Study No:2006-0022 ( NCT No: NCT01283997)
Title:A Phase II study of Minocycline vs. Placebo to Prevent Treatment Induced Neuropathy in Multiple Myeloma
Principal Investigator:Sheeba K. Thomas
Treatment Agent:Minocycline
Study Status:Closed
Study Description:The goal of this clinical research study is to see if MinocinŽ (minocycline)
can help to control nerve damage that causes numbness and tingling in the hands
and feet (neuropathy) in patients receiving thalidomide and/or bortezomib.
Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase II
Treatment Agents:Minocycline
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:N/A
Supported By:N/A
Return Visit:Before each cycle of therapy, approximately every 3-4 weeks.
Home Care:N/A

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sheeba K. Thomas
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults